We help save lives by detecting lung disease early.

Every breath is precious.

Occupational Lung Disease
Lung Nodule Management
Lung Cancer Screening

lungsreen.com
About Lungscreen

Our mission is to ensure that all people at risk of developing lung disease have equitable access to an affordable, safe, reliable and scientifically based lung-screening program to achieve a positive health outcome. Achieving this requires the use of advanced technology by our lung specialists, working collaboratively as part of a multidisciplinary healthcare team.

Lungscreen has a professional clinical board consisting of Radiologists with sub-specialty experience in lung disease, as well as respiratory specialists, occupational physicians, radiation and medical oncologists. The unifying theme across all our work is a commitment to high-quality services aimed at early detection, with the patient at the centre.

Our Services

Our services include, detection of occupational lung disease, lung nodule management and lung cancer screening. In particular, we are proud to be at the forefront of occupational lung disease detection and management.

Occupational lung diseases affect the respiratory system and include Coal Workers ‘Pneumoconiosis’ (CWP), but also include chronic obstructive pulmonary disease, silicosis, emphysema, diffuse dust-related fibrosis and Idiopathic Pulmonary Fibrosis (IPF). Our purpose is to identify early stage and treatable lung disease in workers at risk to protect lung health.

Occupational Lung Disease

At Lungscreen our first and foremost consideration is the welfare of Australian industrial workers. As such, we are proud to offer an all-inclusive lung screening and registry service for coal mine workers and their employers, as well as other industrial workers. This is provided through an effective chest X-ray screening program for the early diagnosis of Coal Mine Dust Lung Diseases as well as other occupational lung diseases. Achieving this requires a unified vision aligned with an innovative and dedicated team of lung specialists. At Lungscreen we have a strong collaborative approach.

Qld Coal Mine Statistics for Current and Former Workers

- 18 coal miners diagnosed with CWP since 2015.
- 54 confirmed cases of mine dust lung diseases, as at Oct 2017.

Coal Workers ‘Pneumoconiosis’ (CWP)

Australia is currently facing a resurgence of the fatal employment-related disease CWP, also known as Black Lung disease. Regulatory changes on 1 January 2017 under the Coal Mine Worker’s Health Scheme require that all Queensland coal mine workers receive a health assessment upon entry to the industry, then at least every 5 years and upon retirement (on a voluntary basis).

The health assessment must include a lung function test through spirometry. A chest X-ray is required at least every 5 years for underground workers and every 10 years for above-ground workers. To ensure early detection of CWP all coal mine workers’ chest X-rays must be dual read against the International Labour Organization (ILO) standard. In 2017 Lungscreen was proud to be appointed by the Department of Natural Resources and Mines to provide this service across Queensland, by Lungscreen’s team of NIOSH B-Reader certified Radiologists commencing May 2018.
Lung Nodule Management

A key group susceptible to lung diseases are patients that are diagnosed with Pulmonary or Nonsolid Lung Nodules "spot on the lung". These nodules can be managed by periodic low-dose CT scans and reviewed by an experienced Radiologist to measure and compare previous images. However, they can potentially develop into lung disease if left unmanaged. We offer an integrated solution for the management of patients who present with lung nodules, including notifications for periodic monitoring and check-ups to ensure patient wellbeing. This comprehensive patient management system in lung nodule management is unique to lungscreen.

Lung Cancer Screening

Traditionally, detection for lung disease occurs when a patient presents to their General Practitioner with an ongoing cough or shortness of breath. However, a major clinical trial performed in the United States of America, named the National Lung Screening Trial (NLST), demonstrated a 20% reduction in lung cancer mortality rates when screening was performed with low dose CT, in comparison with a traditional chest X-ray. There is strong evidence of the advantages of a broader lung screening program, using low dose CT, for those individuals at high risk of developing lung disease. Lungscreen encourages consultation between GP’s and Specialists on appropriate screening options and management available at lungscreen, for patients with a high risk of developing lung disease.

Why Lungscreen?

- A team of FRANZCR Radiologists, experienced in thoracic imaging.
- Qualified B-readers under the National Institute of Occupational Safety and Health (NIOSH).
- Leaders in lung disease diagnosis and management with a dedicated commitment to continual improvement through education, research and training.
- All of our services are delivered by a medical team who are passionate about protecting the lung health of those at risk.
- Lungscreen has a multidisciplinary team of experienced lung experts with a strong clinical knowledge in this field.

The Importance Of Lung Screening

Lung disease is a widespread, growing problem in Australia. While most lung diseases are treatable when detected early, the disease often presents with little or no symptoms until it has progressed into the incurable and advanced disease stage. Our objective at Lungscreen is to provide much-needed lung disease diagnosis and management services for the numerous individuals at risk in an effort to save lives. Our specialist multidisciplinary team of radiologists, respiratory and lung physicians, as well as medical and radiation oncologists, combine to provide a holistic lung disease prevention service firmly focused on patient wellbeing. As such, Lungscreen has 3 divisions at the forefront of lung health strategies including Occupational Lung Disease Services, Lung Nodule Management and Lung Cancer Screening. For more information about Lungscreen visit www.lungscreen.com

Lungscreen Team

Lungscreen has a three-member board of directors including Helen Stevens, Dr Nigel Sommerfeld and Dr Siavash Es’haghi. The inclusion of a team of accredited B-reader radiologists and a Clinical Governance board are critical resources unique to Lungscreen.